National Institutes of Health October 22, 2021

A new, retrospective study of medical and insurance records indicates health care costs for people with a rare disease have been underestimated and are three to five times greater than the costs for people without a rare disease. The study, led by the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS), provides new evidence of the potential impact of rare diseases on public health, suggesting that nationwide medical costs for individuals with rare diseases are on par with those for cancer and heart failure. The study’s results were published Oct. 21 in the Orphanet Journal of Rare Diseases(link is external).

“There needs to be greater public awareness of the large and growing medical footprint of rare diseases...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Healthcare System, Patient / Consumer, Pricing / Spending, Provider, Survey / Study, Trends
Healthcare prices surge 14% in last 5 years: Report
What Fishing Can Teach Us About Lowering Healthcare Costs
Drug Expenditures Surge. Drug Prices Don't.
Weight-Loss Drugs Drive U.S. Prescription Spending
Why Are Cash Prices Lower Than Health Insurance Negotiated Prices?

Share This Article